RAC are also investigating drug combinations in the melanoma pre-clinical (which were not mentioned in the interim results). So we can expect something entirely new in the final results:
The market for Melanoma is dominated by Yervoy (targets CTLA-4) and Opdivo (targets PD-1). It it is expected that PD-1 checkpoint immunotherapy will dominate the market by 2026. https://www.thepharmaletter.com/article/melanoma-drug-sales-set-to-rise-at-5-3-cagr
And, from the investor presentation we know that RAC are specifically looking for PD-1 synergies in melanoma.
- Forums
- ASX - By Stock
- Ann: Race Initiates FTO Melanoma Preclinical Study
RAC are also investigating drug combinations in the melanoma...
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.66 |
Change
0.055(3.43%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.60 | $219.3K | 133.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1821 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.63 | 3465 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.630 |
2 | 5300 | 1.625 |
1 | 7899 | 1.615 |
3 | 12820 | 1.610 |
2 | 994 | 1.605 |
Price($) | Vol. | No. |
---|---|---|
1.640 | 4248 | 2 |
1.645 | 1000 | 1 |
1.650 | 2309 | 2 |
1.655 | 870 | 1 |
1.660 | 4402 | 2 |
Last trade - 10.29am 30/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online